Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
AINU is set to accelerate its expansion footprint, enhance operational capabilities
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Subscribe To Our Newsletter & Stay Updated
